Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931207 | 1.00 | CHRM2 (0.35) | CHRM2CHRM5CHRM1TSHRMAPK1 | |
| SCHEMBL1936624 | 0.78 | — | — | |
| SCHEMBL30189856 | 0.77 | — | — | |
| SCHEMBL19404112 | 0.77 | — | — | |
| SCHEMBL6303714 | 0.77 | — | — | |
| SCHEMBL7933698 | 0.76 | ALDH1A1 (0.56) | CHRM2CHRM5CHRM1TSHRMAPK1 | |
| SCHEMBL7931289 | 0.76 | PDK1 (0.42) | CHRM2CHRM5CHRM1TSHRMAPK1 | |
| SCHEMBL16297461 | 0.76 | — | — | |
| SCHEMBL22454917 | 0.76 | — | — | |
| SCHEMBL12386520 | 0.75 | PDK1 (0.32) | PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994355-B2 | Metallocene-based chiral phosphine or arsine ligands | SOLVIAS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7982064-B2 | Method for preparing ortho-substituted aminoferrocenes | BROCK UNIVERSITY (CA) | 2011-07-19 | — | — | US | disclosed |
| US-20100137588-A1 | METHOD FOR PREPARING ORTHO-SUBSTITUTED AMINOFERROCENES | BROCK UNIVERSITY (CA) | 2010-06-03 | — | — | US | disclosed |
| EP-1709054-B1 | METALLOCENE-BASED CHIRAL PHOSPHINE OR ARSINE LIGANDS | PHOENIX CHEMICALS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20070161762-A1 | Metallocene-based chiral phosphine or arsine ligands | PHOENIX CHEMICALS LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137588-A1 | METHOD FOR PREPARING ORTHO-SUBSTITUTED AMINOFERROCENES | LPO, AOC1, AOC2 | CHRM2 4339/4885CHRM5 4269/4885CHRM1 4130/4885 |
| US-20070161762-A1 | Metallocene-based chiral phosphine or arsine ligands | OSGEP, PHOSPHO1, ITPA | CHRM2 1024/4885CHRM5 697/4885CHRM1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.